Delix

Delix Therapeutics

This biotechnology company develops non-hallucinogenic neuroplasticity-promoting medicines to treat patients with neuropsychiatric and neurodegenerative conditions.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Beckley Psytech

The company develops psychedelic-derived medicines to treat patients with neurological and psychiatric conditions such as treatment-resistant depression and rare headache disorders.

Xylo

The company develops non-hallucinogenic neuroplastogens to treat psychiatric and neurological disorders in patients with unmet medical needs.

Pangea Botanica

This company develops medicines for neurological and mental health disorders using an artificial intelligence platform to discover neuroactive molecules from medicinal plants.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Exin Therapeutics

This company develops an artificial intelligence platform to discover and design neurotherapeutics targeting neural circuits for patients with neurological and neuropsychiatric disorders.